ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Sunday, October 21, 2018

9:00AM-11:00AM
Abstract Number: 448
Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice
Pain Mechanisms – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 692
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment
9:00AM-11:00AM
Abstract Number: 233
TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 63
TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis
Rheumatoid Arthritis – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 767
Tobacco and Systemic Lupus Erythematosus Relationships: Pay Attention to the Retina!
Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity
9:00AM-11:00AM
Abstract Number: 49
Tofacitinib Facilitates the Expansion of Myeloid-Dirived Suppressor Cells and Ameliorates Interstitial Lung Disease in SKG Mice
Rheumatoid Arthritis – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 27
Top-Down Proteomics Coupled with Antibody Sequencing from Single B Cells Reveals a Monoclonal Anti-Sm Clone Present in the Serum of an SLE Patient over Three Years
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 444
Trajectories of Sport or Recreational Activities over Eight Years and Associated Factors in Persons at Risk for Knee Osteoarthritis
Osteoarthritis – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 803
Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry
Systemic Sclerosis and Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 556
Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology
9:00AM-11:00AM
Abstract Number: 23
Treatment with Immune Checkpoint Inhibitors and the Development of Autoantibodies
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 434
Trends in Procedure Type, Patient Characteristics, and Outcomes Among Persons with Knee Osteoarthritis Undergoing Bariatric Surgery, 2005-2014
Osteoarthritis – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 498
Trends in the Incidence of Cardiovascular Diseases in Patients with Rheumatoid Arthritis in Spain: A National Observational Cohort Study of Hospital Discharges
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 493
Trends in the Incidence of SOLID Tumors in Patients with Rheumatoid Arthritis in Spain. a National Observational Cohort Study
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 695
Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment
  • «Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 67
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology